We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Galena Biopharma says it can proceed with clinical trials combining its lead breast cancer vaccine NeuVax with Roche's Herceptin after a team of independent inspectors ruled out safety and futility concerns.